Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL885029 | 0.85 | HSD17B10 (0.57) | APLNRALDH1A1CA2CA12CA1 | |
| SCHEMBL30229484 | 0.85 | HSD17B10 (0.57) | APLNRALDH1A1CA2CA12CA1 | |
| SCHEMBL2317884 | 0.84 | APLNR (0.45) | APLNRALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6177244 | 0.84 | TTR (0.47) | APLNRALDH1A1CYP1A2HTR2AHSD17B10 | |
| SCHEMBL17537954 | 0.83 | ALDH1A1 (0.50) | APLNRALDH1A1CA2MAPTMEN1 | |
| SCHEMBL31299914 | 0.83 | ALDH1A1 (0.44) | APLNRALDH1A1MAPTHSD17B10CYP3A4 | |
| SCHEMBL584252 | 0.82 | APLNR (0.59) | APLNRALDH1A1CA2CA12CA1 | |
| SCHEMBL10391370 | 0.82 | APLNR (0.46) | APLNRALDH1A1CA2CA12CA1 | |
| SCHEMBL2559819 | 0.81 | HTT (0.45) | APLNRALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL15974038 | 0.81 | ACHE (0.50) | APLNRALDH1A1CYP1A2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5376671-A | Cardiovascular disorders, hypotensive agents, anticholesterol agent | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-27 | — | — | US | claimed |
| CN-117964633-B | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117964633-A | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-3355699-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | OncoTherapy Science, Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017168024-A1 | COMPOUNDS WITH ANTIOXIDANT ACTIVITY AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2017-10-05 | — | — | WO | disclosed |
| EP-2958897-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| CN-1286810-C | 2-acyl indol derivatives and their use as anti-tumour agents | BAKST HEALTH AG (CH) | 2006-11-29 | — | — | CN | disclosed |
| US-6867297-B1 | Process for synthesizing 4-substituted azetidinone derivatives | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| CN-1431997-A | 2-acylindole derivatives and their use as antitumor agents | BAKST HEALTH AG (CH) | 2003-07-23 | — | — | CN | disclosed |
| EP-0638552-B1 | PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1017693-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999015525-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-04-01 | — | — | WO | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0638552-A1 | PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | APLNR 2870/4885ALDH1A1 1129/4885CA2 2981/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | APLNR 2870/4885ALDH1A1 1129/4885CA2 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.